Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun-Jul;32(6):1002-3.
doi: 10.3174/ajnr.A2601. Epub 2011 May 19.

Panitumumab (vectibix)

J J Gemmete  1 , S K Mukherji
Affiliations

Panitumumab (vectibix)

J J Gemmete et al. AJNR Am J Neuroradiol. 2011 Jun-Jul.

Abstract

Panitumumab (Vectibix), is a human monoclonal antibody EGFR antagonist indicated as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. This article will present the mechanism of action as well as the clinical role for this monoclonal antibody.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Schematic illustration of the proposed mechanism of panitumumab. Panitumumab is a monoclonal antibody that binds to the extracellular portion of the EGFR preventing dimerization and the cascade that leads to the expression of growth factors. (Illustration courtesy of Carolyn Nowak.)
See this image and copyright information in PMC

References

    1. Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer 2003; 2: 246– 51 - PubMed
    1. Kim GP, Grothey A. Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics 2008; 2: 223– 28 - PMC - PubMed
    1. Keating GM. Spotlight on panitumumab in metastatic colorectal cancer. BioDrugs 2010; 1 24: 275– 78 - PubMed
    1. Keating GM. Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 28 2010; 70: 1059– 78 - PubMed
    1. Hoda D, Simon GR, Garrett CR. Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. Ther Clin Risk Manag 2008; 4: 1221– 27 - PMC - PubMed

MeSH terms